Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions. Common myths:#1: Only older patients need to worry about AD. #2: AD is primarily an inherited genetic disease. #3: Most patients don’t want to know if they are at risk of developing AD. #4: Only high-powered imaging tests can help evaluate for AD. #5: Only…READ MORE

The US Senate passed the Promise to Address Comprehensive Toxics (PACT) Act on August 2, 2022. The PACT healthcare bill is a positive step toward assisting the 3.5 million veterans affected by exposure to toxins during military service. The debate surrounding the PACT legislation drew attention to a stark fact: too many of America’s veterans live with ill health. In 2020, the Veterans Administration National Center for PTSD conducted a…READ MORE

The quality of the food we eat can have profound effects on our health. Researchers have identified many links between the consumption of Western-style diets and several chronic diseases: type 2 diabetes, cardiovascular disease, several types of cancer, and Alzheimer's Disease and Related Dementias (ADRD). Someone with these eating habits tends to consume too much fast food, highly processed (or “junk”) foods, and sugary drinks, and does not eat enough…READ MORE

Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE

Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through a partnership with Raleigh, N.C.-based health technology company uMETHOD Health, the Secaucus-headquartered testing provider added the RestoreU Dementia Panel to its testing portfolio, according to a May 4 announcement. Dr. Michael Racke, Quest’s neurology medical director, said, “With so much attention on emerging therapies for…READ MORE

More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE

Frontotemporal Dementia (FTD) is a neurodegenerative disease that affects two brain structures:  the frontal lobes and the temporal lobes. The location of damage is distinct from that of Alzheimer’s Disease (AD), which is characterized by the degeneration of the brain structure known as the hippocampus. For each of these conditions, neurodegeneration can be readily quantified by the amount of shrinkage (loss of tissue) in these structures, which can be observed…READ MORE

In February 2022, Dr. Federico Canavosio of Integrative Medical Care (IMC) in Vero Beach, FL started applying a new approach to memory care for patients aged 60 and older. IMC began working with medical AI company uMETHOD Health to deploy RestoreU, an evidence-based care program for patients at risk of developing Alzheimer’s Disease (AD), dementia, or other cognitive issues. “Cognitive impairment and related dementias are difficult to treat because they…READ MORE